The abstract is read at the publisher; the summary is JClub's.
In 395 eyes with open-angle glaucoma treated with acellular scleral allograft spacers, 12-month safety showed no endothelial decompensation, endophthalmitis, or sympathetic ophthalmia.
- Why it matters: Real-world evidence is needed to quantify ocular risks of bio-interventional uveoscleral outflow enhancement, including hypotony, sustained IOP elevation, allograft migration, and corneal endothelial effects.
- What they did: Adults with OAG in the prospective multicenter CREST study were followed to 12 months, with adverse events collected at protocol visits and analyzed at the eye level.
- The result: Clinically significant hypotony occurred in 1 eye (0.3%), sustained IOP elevation in 6 eyes (1.5%), serious events in 12 eyes (3.0%), and endothelial cell density changed by -6.5% in 91 eyes with paired microscopy.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.